Avadel Pharmaceuticals PLC AVDL:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
7.56quote price arrow down-0.17 (-2.20%)
Volume
574,696
52 week range
4.00 - 13.49

...

Loading . . .

KEY STATS

  • Open7.60
  • Day High7.80
  • Day Low7.21
  • Prev Close7.56
  • 52 Week High13.49
  • 52 Week High Date04/27/20
  • 52 Week Low4.00
  • 52 Week Low Date03/18/20
  • Market Cap440.14M
  • Shares Out58.22M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta1.38
  • 1 Year % Change-25.59

RATIOS/PROFITABILITY

  • EPS (TTM)-0.08
  • P/E (TTM)-99.47
  • Fwd P/E (NTM)-7.09
  • EBITDA (MRQ)-27.353M
  • ROE (MRQ)8.93%
  • Revenue (MRQ)33.33M
  • Gross Margin (MRQ)75.53%
  • Net Margin (MRQ)19.33%
  • Debt To Equity (MRQ)73.90%

EVENTS

  • Earnings Date03/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Avadel Pharmaceuticals PLC News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in...
Geoffrey Glass
Non-Executive Chairman
Gregory Divis Jr.
Chief Executive Officer
Thomas McHugh
Chief Financial Officer
Address
Block 10-1 Blanchardstown Corporate Park
Ballycoolin
Dublin
15
Ireland